(P081) An Analysis of Soft Tissue Anatomy and Tracking of the Prostate Using Transperineal Ultrasound

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Transperineal ultrasound allows clinicians to both detect the anatomy of the pelvis in comparable detail with MRI and appreciate intrafraction motion of the prostate and nearby critical structures in order to deliver more precise radiotherapy.

P081: Figure

Vivek N. Patel, MD, Kyle Padgett, PhD, Elizabeth Bossart, PhD, Laura Freedman, MD, Adrian Ishkanian, MD, MSc, Alan Pollack, MD, PhD, Matthew Abramowitz, MD; University of Miami Miller School of Medicine

Purpose and Objectives: Transperineal ultrasound (TPUS) imaging is capable of providing low-cost, noninvasive, and accurate anatomic imaging of the male pelvis without the use of ionizing radiation. TPUS imaging can also be utilized during external beam radiation therapy (EBRT) to aid in treatment simulation to improve visualization of soft tissue anatomy. Furthermore, this modality may be used during daily treatment delivery to localize the prostate and organs at risk (OARs) within the pelvis using native anatomic structures. Thus, this procedure would allow clinicians to perform precise intrafraction prostate-tracking. Magnetic resonance imaging (MRI) is currently employed as an adjunct to CT for enhanced soft tissue imaging. However, this study requires image fusion with CT, which can be a source of uncertainty and can not be used during treatment. In contrast, TPUS is portable and functions via benign acoustic waves, which have not been shown to affect the treatment field. Apart from these inherent advantages, TPUS imaging is more cost-effective than MRI. Given these advantageous features, we demonstrate that TPUS can identify structures of the male pelvis similar to those images gathered from an MRI prior to simulation.

Materials and Methods: In order to evaluate the effectiveness of TPUS imaging, we analyzed the data collected for seven patients as part of an institutional review board (IRB)-approved clinical trial evaluating TPUS for prostate-tracking. These patients had pathologically confirmed prostate cancer and underwent definitive treatment with external radiation. All patients had a 3T MRI prior to CT simulation. During CT simulation, the patients had a 3D TPUS (Clarity system, Elekta). These images were subsequently transferred to the Clarity Automated Fusion and Contouring Workstation (V.3.0.0.109) and were fused. Thereafter, the fused images were transferred to MIM Maestro (V.6.1.7DB04-0B) for contouring. The MRI images for all patients were contoured for the prostate and OARs, including the bladder, rectum, seminal vesicles, penile bulb, and the genitourinary diaphragm. The MRI-contoured structures were subsequently overlaid on the CT and TPUS.

Results: When comparing the contoured images on the MRI and TPUS, it is apparent that both modalities are superior to CT and similarly capable of demarcating soft tissue anatomy, such as the penile bulb (green), bladder (magenta), urethra (blue), genitourinary diaphragm (purple), prostate (red), seminal vesicles (orange), and rectum (yellow). We have provided an example of an MRI-contoured structure set overlaid on CT and US to visually portray this observation. The advantage of the TPUS during simulation and treatment can be extrapolated from these contoured images. These images may also serve as an atlas to delineate structures that can be visualized during radiotherapy. 

Conclusions: TPUS allows clinicians to both detect the anatomy of the pelvis in comparable detail with MRI and appreciate intrafraction motion of the prostate and nearby critical structures in order to deliver more precise radiotherapy.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content